// App-Quantinova.ai

395 : Cost-effectiveness analysis of pembrolizumab for BCG-unresponsive carcinoma in situ of the bladder.

Researchers

Presenter

  • Vidit Sharma

Principal Investigators

  • Kevin Wymer

  • Christopher Saigal

  • Karim Chamie

  • Mark S. Litwin

  • Vignesh T. Packiam

  • Matthew Mossanen

  • Lance C. Pagliaro

  • Bijan J Borah

  • Stephen A. Boorjian

Medical Centers

  • UCLA Department of Radiology, Los Angeles, CA

  • Mayo Clinic Minnesota, Rochester, MN

  • University of California, Los Angeles, Los Angeles, CA

  • Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA

  • University of California Los Angeles Department of Radiological Sciences, Los Angeles, CA

  • Mayo Clinic, Rochester, MN

  • Brigham and Women's Hospital, Brookline, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Gemcitabine

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved